|
Species/phenotype
|
n
|
% Susceptible
|
|---|
|
C/T
|
P/T
|
FEP
|
CAZ
|
CRO
|
ATM
|
MEM
|
IMI
|
LVX
|
AMK
|
|---|
|
P. aeruginosa
|
|
FEP-nonsusceptible
|
257
|
82.1
|
12.5
|
0
|
18.3
|
NA
|
9.3
|
38.9
|
35.4
|
31.1
|
86.4
|
|
CAZ-nonsusceptible
|
266
|
81.6
|
10.2
|
21.1
|
0
|
NA
|
12.8
|
46.6
|
41.0
|
38.4
|
88.7
|
|
MEM-nonsusceptible
|
312
|
87.8
|
41.7
|
49.7
|
54.5
|
NA
|
31.1
|
0
|
7.1
|
30.1
|
90.1
|
|
P/T-nonsusceptible
|
317
|
86.8
|
0
|
29.0
|
24.6
|
NA
|
12.3
|
42.6
|
40.4
|
36.0
|
91.2
|
|
MDR
|
181
|
76.2
|
8.8
|
12.7
|
17.1
|
NA
|
3.9
|
17.7
|
15.5
|
17.7
|
82.3
|
|
Enterobacterales
|
|
FEP-nonsusceptible
|
204
|
59.3
|
50.5
|
0
|
10.3
|
2.0
|
9.3
|
84.8
|
78.4
|
31.4
|
91.7
|
|
CAZ-nonsusceptible
|
321
|
52.7
|
43.9
|
43.0
|
0
|
3.7
|
11.2
|
89.4
|
81.9
|
52.0
|
95.0
|
|
MEM-nonsusceptible
|
39
|
12.8
|
10.3
|
20.5
|
12.8
|
7.7
|
7.7
|
0
|
0
|
38.5
|
84.6
|
|
P/T-nonsusceptible
|
232
|
36.2
|
0
|
56.5
|
22.4
|
16.4
|
22.8
|
84.9
|
80.2
|
66.4
|
94.0
|
|
MDR
|
238
|
49.6
|
42.9
|
30.7
|
8.8
|
7.1
|
9.2
|
84.9
|
73.1
|
36.6
|
92.4
|
|
K. pneumoniaec
|
|
FEP-nonsusceptible
|
77
|
63.6
|
49.4
|
0
|
3.9
|
2.6
|
5.2
|
80.5
|
79.2
|
28.6
|
90.9
|
|
CAZ-nonsusceptible
|
87
|
63.2
|
47.1
|
14.9
|
0
|
8.1
|
11.5
|
82.8
|
80.5
|
33.3
|
92.0
|
|
P/T-nonsusceptible
|
57
|
45.6
|
0
|
31.6
|
19.3
|
29.8
|
31.6
|
73.7
|
70.2
|
47.4
|
87.7
|
|
ESBL screen-positived
|
85
|
67.1
|
52.9
|
11.8
|
5.9
|
0
|
9.4
|
82.4
|
80.0
|
32.9
|
91.8
|
|
MDR
|
66
|
59.1
|
45.5
|
1.5
|
0
|
0
|
0
|
77.3
|
75.8
|
25.8
|
89.4
|
|
E. colic
|
|
FEP-nonsusceptible
|
55
|
87.3
|
80.0
|
0
|
12.7
|
0
|
12.7
|
98.2
|
98.2
|
14.6
|
92.7
|
|
CAZ-nonsusceptible
|
64
|
84.4
|
75.0
|
25.0
|
0
|
3.1
|
6.3
|
98.4
|
98.4
|
29.7
|
95.3
|
|
P/T-nonsusceptible
|
29
|
69.0
|
0
|
62.1
|
44.8
|
48.3
|
51.7
|
96.6
|
96.6
|
51.7
|
93.1
|
|
ESBL screen-positived
|
74
|
86.5
|
79.7
|
25.7
|
16.2
|
0
|
16.2
|
98.7
|
98.7
|
25.7
|
94.6
|
|
MDR
|
45
|
82.2
|
73.3
|
4.4
|
0
|
0
|
2.2
|
97.8
|
97.8
|
11.1
|
93.3
|
|
P. aeruginosa + Enterobacterales
|
|
FEP-nonsusceptible
|
461
|
72.0
|
29.3
|
0
|
14.7
|
NA
|
9.3
|
59.2
|
54.4
|
31.2
|
88.7
|
|
CAZ-nonsusceptible
|
587
|
65.8
|
28.6
|
33.0
|
0
|
NA
|
11.9
|
70.0
|
63.4
|
45.8
|
92.2
|
|
MEM-nonsusceptible
|
351
|
79.5
|
38.2
|
46.4
|
49.9
|
NA
|
28.5
|
0
|
6.3
|
31.1
|
89.5
|
|
P/T-nonsusceptible
|
549
|
65.4
|
0
|
40.6
|
23.7
|
NA
|
16.8
|
60.5
|
57.2
|
48.8
|
92.4
|
|
MDR
|
419
|
61.1
|
28.2
|
22.9
|
12.4
|
NA
|
6.9
|
55.8
|
48.2
|
28.4
|
88.1
|
- a Abbreviations: C/T, ceftolozane/tazobactam; P/T, piperacillin/tazobactam; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; ATM, aztreonam; MEM, meropenem; IMI, impenem; LVX, levofloxacin; AMK, amikacin; NA, not available
- b Table does not show results for colistin because P. aeruginosa and Enterobacterales cannot be categorized as susceptible to colistin using CLSI M100 (2020) MIC breakpoint criteria
- c MEM-nonsusceptible E. coli (n = 1) and MEM- nonsusceptible K. pneumoniae (n = 15) were not included in the table because there were too few isolates
- d ESBL screen-positive isolates of K. pneumoniae and E. coli were identified by a CRO-nonsusceptible phenotype
